Nurix Therapeutics (NRIX) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

Nurix Therapeutics Revenue Highlights


Latest Revenue (Y)

$76.99M

Latest Revenue (Q)

$12.09M

Main Segment (Y)

Collaboration Revenue

Nurix Therapeutics Revenue by Period


Nurix Therapeutics Revenue by Year

DateRevenueChange
2023-11-30$76.99M99.31%
2022-11-30$38.63M29.84%
2021-11-30$29.75M66.95%
2020-11-30$17.82M-42.73%
2019-11-30$31.11M-16.91%
2018-11-30$37.45M-

Nurix Therapeutics generated $76.99M in revenue during NA 2023, up 99.31% compared to the previous quarter, and up 205.58% compared to the same period a year ago.

Nurix Therapeutics Revenue by Quarter

DateRevenueChange
2024-05-31$12.09M-27.09%
2024-02-29$16.59M9.41%
2023-11-30$15.16M-17.91%
2023-08-31$18.47M-39.80%
2023-05-31$30.68M141.83%
2023-02-28$12.69M87.01%
2022-11-30$6.78M-37.14%
2022-08-31$10.79M-5.61%
2022-05-31$11.43M18.82%
2022-02-28$9.62M30.08%
2021-11-30$7.40M-27.86%
2021-08-31$10.25M44.58%
2021-05-31$7.09M41.51%
2021-02-28$5.01M-25.09%
2020-11-30$6.69M63.75%
2020-08-31$4.08M-2.32%
2020-05-31$4.18M46.02%
2020-02-29$2.86M53.81%
2019-11-30$1.86M-82.40%
2019-08-31$10.58M-

Nurix Therapeutics generated $12.09M in revenue during Q2 2024, up -27.09% compared to the previous quarter, and up 95.33% compared to the same period a year ago.

Nurix Therapeutics Revenue Breakdown


Nurix Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceNov 23
Collaboration Revenue$56.99M
License Revenue$20.00M

Nurix Therapeutics's latest annual revenue breakdown by segment (product or service), as of Nov 23: Collaboration Revenue (74.02%), and License Revenue (25.98%).

Quarterly Revenue by Product

Product/ServiceMay 24Nov 23Aug 23May 23
License Revenue----
Collaboration Revenue$12.09M$27.84M$18.47M$10.68M

Nurix Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of May 24: Collaboration Revenue (100.00%).

Nurix Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
KYMRKymera Therapeutics$78.59M$10.29M
ARVNArvinas$78.50M$76.50M
NRIXNurix Therapeutics$76.99M$12.09M
FHTXFoghorn Therapeutics$34.16M$6.89M
RLAYRelay Therapeutics$25.55M-
STOKStoke Therapeutics$8.78M$4.22M
GBIOGeneration Bio$5.90M$4.06M
STTKShattuck Labs$1.66M$1.61M
PLRXPliant Therapeutics$1.58M-
LYELLyell Immunopharma$130.00K$3.00K
BDTXBlack Diamond Therapeutics--
CCCCC4 Therapeutics--
NKTXNkarta--
ELYMEliem Therapeutics--
PRLDPrelude Therapeutics--
SANASana Bio--
GLUEMonte Rosa Therapeutics-$4.70M

NRIX Revenue FAQ


Nurix Therapeutics's yearly revenue for 2023 was $76.99M, representing an increase of 99.31% compared to 2022. The company's yearly revenue for 2022 was $38.63M, representing an increase of 29.84% compared to 2021. NRIX's yearly revenue for 2021 was $29.75M, representing an increase of 66.95% compared to 2020.

Nurix Therapeutics's quarterly revenue for Q2 2024 was $12.09M, a -27.09% decrease from the previous quarter (Q1 2024), and a -60.58% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $16.58M, a 9.41% increase from the previous quarter (Q4 2023), and a 30.74% increase year-over-year (Q1 2023). NRIX's quarterly revenue for Q4 2023 was $15.16M, a -17.91% decrease from the previous quarter (Q3 2023), and a 123.49% increase year-over-year (Q4 2022).

Nurix Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 158.78%, and for the last 5 years (2019-2023) was 147.43%.

Nurix Therapeutics's revenue streams in v 23 are Collaboration Revenue, and License Revenue. Collaboration Revenue generated $56.99M in revenue, accounting 74.02% of the company's total revenue License Revenue generated $20M in revenue, accounting 25.98% of the company's total revenue

For the fiscal year ending Nov 23, the largest source of revenue of Nurix Therapeutics was Collaboration Revenue. This segment made a revenue of $56.99M, representing 74.02% of the company's total revenue.